Showing 68 news articles about People with limited treatment options

Filters Content type: Editors' picks Topic: People with limited treatment options

HIV treatment for people who have a strain of HIV that is resistant to multiple drug classes or who cannot take other HIV medications.

New & experimental HIV treatments

Trogarzo [Ibalizumab] Label Updated With 90-Second IV Push Loading Dose

Editor's pick
Infectious Disease Advisor
20 December 2023
People with limited treatment options

Sunlenca Remains Active Against Drug-Resistant HIV

Editor's pick
POZ
19 October 2023
People with limited treatment options

Intramuscular Administration of HIV Treatment Ibalizumab Compared With IV Infusion

Editor's pick
Monthly Prescribing Reference
17 October 2023
People with limited treatment options

Long-Term Outcomes of Fostemsavir in HTE Adults With Advanced HIV

Editor's pick
Infectious Disease Advisor
17 October 2023
People with limited treatment options

Study Bite: Switching to B/F/TAF Plus Doravirine in Multidrug-Resistant PLWH

Editor's pick
TheBodyPro
5 May 2023
People with limited treatment options

WEP Clinical has partnered with TaiMed Biologics to launch a Trogarzo named patient program

Editor's pick
WEP Clinical press release
24 March 2023
Injectable & long-acting HIV treatment

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

Editor's pick
POZ
10 November 2022
HIV treatment

IDWeek 2022 Study Bites: What’s New in HIV Antiretroviral Therapy

Editor's pick
TheBodyPro
10 November 2022
Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
People with limited treatment options

Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience

Editor's pick
NATAP
26 October 2022
People with limited treatment options

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
New & experimental HIV treatments

5 FDA decisions to watch in the fourth quarter

Editor's pick
BioPharma Dive
3 October 2022
New & experimental HIV treatments

Fostemsavir Plus Optimized Background Therapy May Be Viable for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
30 June 2022
Injectable & long-acting HIV treatment

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Editor's pick
Gilead Sciences press release
25 June 2022
People with limited treatment options

Theratechnologies to Focus Its Commercialization Activities on the North American Territory

Editor's pick
Theratechnologies press release
28 April 2022
Injectable & long-acting HIV treatment

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

Editor's pick
GlobeNewswire
22 September 2021
Pharmaceutical industry

Gilead files long-acting HIV med for patients running out of options

Editor's pick
FierceBiotech
1 July 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
HIV treatment

Top 10 HIV Clinical Developments of 2020

Editor's pick
TheBodyPro
1 December 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020
People with limited treatment options

Patients with HIV and four-class drug resistance have high disease burden

Editor's pick
Healio
11 October 2020
People with limited treatment options

Heavily Pretreated US HIV Patients Face Clinical Hurdles, Higher Death Risk

Editor's pick
NATAP
6 July 2020